27577957|t|Adenosine arrests breast cancer cell motility by A3 receptor stimulation
27577957|a|In neutrophils, adenosine triphosphate (ATP) release and autocrine purinergic signaling regulate coordinated cell motility during chemotaxis. Here, we studied whether similar mechanisms regulate the motility of breast cancer cells. While neutrophils and benign human mammary epithelial cells (HMEC) form a single leading edge, MDA-MB-231 breast cancer cells possess multiple leading edges enriched with A3 adenosine receptors. Compared to HMEC, MDA-MB-231 cells overexpress the ectonucleotidases ENPP1 and CD73, which convert extracellular ATP released by the cells to adenosine that stimulates A3 receptors and promotes cell migration with frequent directional changes. However, exogenous adenosine added to breast cancer cells or the A3 receptor agonist IB-MECA dose - dependently arrested cell motility by simultaneous stimulation of multiple leading edges, doubling cell surface areas and significantly reducing migration velocity by up to 75 %. We conclude that MDA-MB-231 cells, HMEC, and neutrophils differ in the purinergic signaling mechanisms that regulate their motility patterns and that the subcellular distribution of A3 adenosine receptors in MDA-MB-231 breast cancer cells contributes to dysfunctional cell motility. These findings imply that purinergic signaling mechanisms may be potential therapeutic targets to interfere with the motility of breast cancer cells in order to reduce the spread of cancer cells and the risk of metastasis.
27577957	0	9	Adenosine	T114,T121,T123	C0001443
27577957	10	17	arrests	T169	C0205245
27577957	18	36	breast cancer cell	T025	C1512505
27577957	37	45	motility	T040	C0007608
27577957	49	60	A3 receptor	T116,T192	C0664494
27577957	61	72	stimulation	T070	C1948023
27577957	76	87	neutrophils	T025	C0027950
27577957	89	111	adenosine triphosphate	T114,T121,T123	C0001480
27577957	113	116	ATP	T114,T121,T123	C0001480
27577957	118	125	release	T169	C1283071
27577957	130	139	autocrine	T042	C0596138
27577957	140	160	purinergic signaling	T044	C3158762
27577957	161	169	regulate	T038	C0678661
27577957	182	195	cell motility	T040	C0007608
27577957	203	213	chemotaxis	T043	C0008018
27577957	248	258	mechanisms	T169	C0441712
27577957	259	267	regulate	T038	C0678661
27577957	272	280	motility	T040	C1510470
27577957	284	303	breast cancer cells	T025	C1512505
27577957	311	322	neutrophils	T025	C0027950
27577957	327	333	benign	T080	C0205183
27577957	334	347	human mammary	T023	C0929301
27577957	348	364	epithelial cells	T025	C0014597
27577957	366	370	HMEC	T025	C0014597
27577957	379	385	single	T081	C0205171
27577957	386	398	leading edge	T026	C1621433
27577957	400	410	MDA-MB-231	T050	C3898556
27577957	411	430	breast cancer cells	T025	C1512505
27577957	439	447	multiple	T081	C0439064
27577957	448	461	leading edges	T026	C1621433
27577957	476	498	A3 adenosine receptors	T116,T192	C0664494
27577957	512	516	HMEC	T025	C0014597
27577957	518	528	MDA-MB-231	T050	C3898556
27577957	529	534	cells	T025	C1512505
27577957	535	546	overexpress	T045	C1514559
27577957	551	574	ectonucleotidases ENPP1	T116,T126	C0084070
27577957	579	583	CD73	T116,T126,T129	C0000530
27577957	599	612	extracellular	T026	C0521119
27577957	613	616	ATP	T114,T121,T123	C0001480
27577957	617	625	released	T169	C1283071
27577957	633	638	cells	T025	C0007634
27577957	642	651	adenosine	T114,T121,T123	C0001443
27577957	657	667	stimulates	T070	C1948023
27577957	668	680	A3 receptors	T116,T192	C0664494
27577957	685	693	promotes	T052	C0033414
27577957	694	708	cell migration	T043	C1622501
27577957	714	722	frequent	T079	C0332183
27577957	723	734	directional	T040	C2246452
27577957	735	742	changes	T169	C0392747
27577957	763	772	adenosine	T114,T121,T123	C0001443
27577957	773	778	added	T169	C1524062
27577957	782	801	breast cancer cells	T025	C1512505
27577957	809	820	A3 receptor	T116,T192	C0664494
27577957	821	828	agonist	T121	C2987634
27577957	829	836	IB-MECA	T114	C0250131
27577957	837	841	dose	T081	C0178602
27577957	844	855	dependently	T080	C1701901
27577957	856	864	arrested	T169	C0205245
27577957	865	878	cell motility	T040	C0007608
27577957	882	894	simultaneous	T079	C0521115
27577957	895	906	stimulation	T070	C1948023
27577957	910	918	multiple	T081	C0439064
27577957	919	932	leading edges	T026	C1621433
27577957	934	942	doubling	T052	C1705764
27577957	943	955	cell surface	T026	C0699040
27577957	956	961	areas	T082	C0205146
27577957	980	988	reducing	T080	C0392756
27577957	989	998	migration	T043	C1622501
27577957	999	1007	velocity	T081	C0439830
27577957	1040	1050	MDA-MB-231	T050	C3898556
27577957	1051	1056	cells	T025	C1512505
27577957	1058	1062	HMEC	T025	C0014597
27577957	1068	1079	neutrophils	T025	C0027950
27577957	1094	1114	purinergic signaling	T044	C3158765
27577957	1115	1125	mechanisms	T169	C0441712
27577957	1131	1139	regulate	T038	C0678661
27577957	1146	1154	motility	T040	C0007608
27577957	1155	1163	patterns	T082	C0449774
27577957	1177	1188	subcellular	T026	C1258076
27577957	1189	1201	distribution	T169	C1704711
27577957	1205	1227	A3 adenosine receptors	T116,T192	C0664494
27577957	1231	1241	MDA-MB-231	T050	C3898556
27577957	1242	1261	breast cancer cells	T025	C1512505
27577957	1277	1290	dysfunctional	T077	C3887504
27577957	1291	1304	cell motility	T040	C0007608
27577957	1332	1352	purinergic signaling	T044	C3158765
27577957	1353	1363	mechanisms	T169	C0441712
27577957	1371	1380	potential	T080	C3245505
27577957	1381	1392	therapeutic	T169	C0302350
27577957	1393	1400	targets	T169	C1521840
27577957	1404	1418	interfere with	T169	C0521102
27577957	1423	1431	motility	T040	C0007608
27577957	1435	1454	breast cancer cells	T025	C1512505
27577957	1467	1473	reduce	T080	C0392756
27577957	1478	1484	spread	T080	C0332261
27577957	1488	1500	cancer cells	T025	C0334227
27577957	1509	1513	risk	T078	C0035647
27577957	1517	1527	metastasis	T046	C4255448